MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

Начало・Списък с акции・Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

180.19 0.48

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

176.13

Максимум

181.91

Ключови измерители
By Trading Economics
Приходи	47M 4.8M
Продажби	2.3M 48M
Марж на печалбата	10.177
Служители	68
EBITDA	50M 9.7M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+1.74% upside

Дивиденти
By Dow Jones
Следващи печалби	6.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	763M 3.4B
Предишно отваряне	179.71
Предишно затваряне	180.19

Настроения в новините

By Acuity

42%

58%

124 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

102.5 / 109.24 Подкрепа & съпротива

Ligand Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.10.2025 г., 23:30 ч. UTC

Горещи акции

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2.10.2025 г., 21:21 ч. UTC

Печалби

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3.10.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2.10.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2.10.2025 г., 23:39 ч. UTC

Пазарно говорене

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2.10.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2.10.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2.10.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2.10.2025 г., 23:00 ч. UTC

Пазарно говорене

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2.10.2025 г., 22:54 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Scales's JV Buyout Lauded by Bull -- Market Talk

2.10.2025 г., 22:54 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Global Forex and Fixed Income Roundup: Market Talk

2.10.2025 г., 22:46 ч. UTC

Пазарно говорене

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2.10.2025 г., 22:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.10.2025 г., 21:17 ч. UTC

Придобивния, сливания и поглъщания

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Energy & Utilities Roundup: Market Talk

2.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

2.10.2025 г., 20:49 ч. UTC

Придобивния, сливания и поглъщания

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2.10.2025 г., 20:00 ч. UTC

Придобивния, сливания и поглъщания

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2.10.2025 г., 19:20 ч. UTC

Пазарно говорене

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2.10.2025 г., 19:10 ч. UTC

Пазарно говорене

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2.10.2025 г., 19:04 ч. UTC

Пазарно говорене

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2.10.2025 г., 18:45 ч. UTC

Придобивния, сливания и поглъщания

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2.10.2025 г., 18:45 ч. UTC

Придобивния, сливания и поглъщания

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2.10.2025 г., 18:44 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2.10.2025 г., 18:44 ч. UTC

Придобивния, сливания и поглъщания

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2.10.2025 г., 18:44 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2.10.2025 г., 18:43 ч. UTC

Придобивния, сливания и поглъщания

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Сравнение с други в отрасъла

Ценова промяна

Ligand Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

1.74% нагоре

12-месечна прогноза

Среден 182.2 USD 1.74%

Висок 206 USD

Нисък 155 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Ligand Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Ligand Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

102.5 / 109.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

124 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.